A Phase 4 interventional study of Casodex 150mg and Radiotherapy in Prostate Cancer, sponsored by AstraZeneca. Completed at 9 sites in Turkey. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-01-25.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing bicalutamide in Prostatic Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. bicalutamide · Prostatic Neoplasms.
Among the 55 studies testing bicalutamide in Prostatic Neoplasms, this one is the 18th largest by planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2003, is one of 5 in phase 4, and was the 23rd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →5 of the 55 studies testing bicalutamide in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Martin T. King, MD, PhD · Sites in United States
Ages 18+ · Men only
Marco Lorenzo Bonu · Sites in Italy
Ages 18–80 · Men only
Washington University School of Medicine · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
bicalutamide: first FDA approval 1995 (CASODEX). What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 21 · Phase 3 22 · Phase 4 5
First in 1994; this study’s year is marked. 3 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 53 across the 54 interventional studies. Of the 42 that completed or were terminated, 10 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 55 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
91 studies in Prostatic Neoplasms by AstraZeneca: 15 open now, 29 under way, 8 of them phase 3. Of 58 finished, 11 (19%) have results posted.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 27th largest by planned enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2003, is one of 4 in phase 4, and was the 17th registered.
AstraZeneca’s Prostatic Neoplasms studies by the year they started, since 1994.
5 of the studies testing bicalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00223145Phase 3Abdenour NabidStudy on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone | 2026-12-31 |
| NCT07393867Martin T. King, MD, PhDAndrogen-responsive POSLUMA-guided Intra-prostatic Boost | 2026-12-15 |
| NCT07783282Astellas Pharma Global Development, Inc.A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer | 2027-04-30 |
| NCT04025372Brigham and Women's HospitalINTREPId (INTermediate Risk Erection PreservatIon Trial) | 2027-10-01 |
| NCT07593079Washington University School of MedicineProstate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer | 2027-11-14 |
Add all 5 to your calendar (.ics) → With an account.
Among the 55 studies testing bicalutamide in Prostatic Neoplasms, from their registry updates:
Among AstraZeneca’s 91 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to examine the value of prophylactic versus therapeutic breast radiotherapy in Casodex monotherapy induced gynaecomastia and/or breast pain. Patients will receive either prophylactic radiotherapy to the breast at a dose of 12Gy (as two fractions of 6 Gy in consecutives days), or will not receive any radiotherapy prior to commencing CASODEX 150mg monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To examine the value of prophylactic versus therapeutic breast radiotherapy in Casodex monotherapy induced gynaecomastia and/or breast pain
To examine the tolerability of radiotherapy to male breast
To examine the tolerability of Casodex 150mg in localized and locally advanced prostate cancer patients
To examine the efficacy of Casodex 150mg in prostate cancer patients
This study is completed, as verified in Jan 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bicalutamide